Dry Eye Disease: What Causes It, When Do Symptoms Require Prescription Treatment, and How Do You Choose Between Cyclosporine and Lifitegrast?

Research-informed explainer — last updated April 12, 2026

Dry eye disease is not simply "not enough tears" — it is a chronic inflammatory condition involving the tear film, ocular surface, and meibomian glands, and the majority of moderate-to-severe cases require prescription anti-inflammatory treatment rather than lubricating drops alone. The decision between cyclosporine (Restasis/Cequa) and lifitegrast (Xiidra) depends on which component of the inflammatory cycle is most active, how quickly you need symptom relief, and how your eyes have responded to first-line interventions.

This article draws on research from five specialist physicians. Sandeep Jain, M.D., at the University of Illinois Hospital, contributed to the TFOS DEWS II pathophysiology report (1,683 citations) — the authoritative mechanistic framework for understanding what drives dry eye at a cellular level. Reza Dana, M.D., MSE, MPH, Professor of Ophthalmology at Harvard Medical School and Director of the Cornea, Ocular Surface and External Disease Service at Massachusetts Eye and Ear, co-authored the TFOS DEWS II management and therapy report (1,343 citations) and a study documenting the substantial impact of dry eye on vision-related quality of life (826 citations). Deborah Jacobs, M.D., at Massachusetts General Hospital, contributed to the TFOS DEWS II pain and sensation report (619 citations) and published clinical guidelines for dry eye associated with Sjogren disease (208 citations). Felipe Medeiros, M.D., at Bascom Palmer Eye Institute, published on ocular surface disease prevalence in glaucoma patients (617 citations) — critical for the large population of patients whose glaucoma drops are worsening their dry eye. David Hardten, M.D., Founding Partner and Director of Clinical Research at Minnesota Eye Consultants, contributed to the clinical trial of the LipiFlow thermal pulsation system for meibomian gland dysfunction (269 citations).

What actually causes dry eye disease

The TFOS DEWS II pathophysiology report, co-authored by Dr. Jain, describes dry eye as a "vicious cycle" driven by three interconnected components:

Tear film instability: A healthy tear film has three layers — a mucin layer anchored to the conjunctival surface, an aqueous layer produced by the lacrimal glands, and a lipid layer secreted by the meibomian glands in the eyelids. Disruption of any layer destabilizes the film, leading to rapid evaporation between blinks and hyperosmolarity (salt concentration rises as water evaporates).

Inflammation: Hyperosmolarity triggers an inflammatory cascade on the ocular surface, releasing cytokines that damage conjunctival and corneal cells. T lymphocytes infiltrate the lacrimal glands, reducing aqueous secretion and perpetuating the cycle. This inflammation is why lubricating drops alone rarely resolve moderate dry eye — they replace water but do not stop the inflammatory damage.

Meibomian gland dysfunction (MGD): The meibomian glands run along the upper and lower eyelid margins, secreting the lipid layer that prevents tear evaporation. In MGD — the most common form of dry eye — these glands become obstructed and atrophied. Without an adequate lipid layer, tears evaporate between blinks within 3–5 seconds rather than the normal 10 seconds or more. MGD is present in an estimated 50–70% of dry eye patients.

Aqueous deficiency dry eye — insufficient tear production — is less common and more closely associated with autoimmune conditions like Sjogren syndrome, rheumatoid arthritis, and lupus. Dr. Jacobs's clinical guidelines for Sjogren-associated dry eye describe a more aggressive treatment approach for this subtype, including earlier use of autologous serum tears and immunomodulatory systemic therapy.

Who is at higher risk

• Women (hormonal changes after menopause significantly increase risk)
• Age over 50
• Contact lens wearers (lens wear disrupts the lipid layer)
• Prolonged screen time (reduced blink rate during screen use accelerates evaporation)
• Antihistamines, antidepressants, diuretics, and beta-blockers (all reduce tear production)
• Prior refractive surgery (LASIK transects corneal nerves that regulate tear reflex)
• Glaucoma patients using preserved eye drops

The last point is clinically important. Dr. Medeiros's study at Bascom Palmer Eye Institute found that 59% of open-angle glaucoma patients had signs and/or symptoms of ocular surface disease. The preservative benzalkonium chloride (BAK) in most glaucoma drops is directly toxic to conjunctival and corneal cells, worsening or causing dry eye. Managing both conditions requires coordinating preservative-free glaucoma drops where possible.

When lubricating drops are not enough

Over-the-counter artificial tears are appropriate first-line treatment for mild dry eye — symptoms present but not disrupting daily activities, no significant staining on exam. However, when symptoms interfere with reading, driving, or screen use, or when the cornea shows punctate epithelial erosions on slit-lamp exam, prescription treatment is indicated.

Dr. Dana's quality-of-life study quantified what patients already know: even moderate dry eye significantly impairs reading ability, driving, and professional activities, with scores comparable to moderate angina. Waiting for symptoms to become severe before prescribing is not consistent with the evidence on functional impact.

Cyclosporine vs. lifitegrast

Both drugs target the T-cell inflammatory cycle on the ocular surface but at different points in the pathway.

Cyclosporine (Restasis 0.05%, Cequa 0.09%): Inhibits calcineurin in T lymphocytes, reducing the production of inflammatory cytokines (particularly IL-2) that damage the lacrimal gland and ocular surface. FDA-approved since 2003. Onset of effect is slow — 3 to 6 months for full benefit. The main side effect is burning on instillation, which improves over time for most patients.

Lifitegrast (Xiidra 5%): Blocks the LFA-1/ICAM-1 interaction that allows T cells to adhere to and infiltrate the ocular surface. FDA-approved in 2016. Phase 3 trials showed statistically significant symptom improvement as early as two weeks, with sustained benefit at three months. The main side effect is a dysgeusia (unusual taste) shortly after instillation in approximately 25% of patients, due to nasolacrimal drainage.

The TFOS DEWS II management report, co-authored by Dr. Dana, recommends both as second-line options after lubricating drops have failed. In clinical practice, some physicians prefer lifitegrast when faster symptom relief is a priority (given its earlier onset), while cyclosporine may be preferred when the primary goal is restoring lacrimal gland function over a longer course. The drugs can be used together in refractory cases.

Procedural and adjunct treatments

Punctal plugs: Small silicone or collagen plugs inserted into the tear drainage channels (puncta) prevent tears from draining away. Effective for aqueous deficiency dry eye; less beneficial when evaporation is the primary problem.

LipiFlow thermal pulsation: A device that applies controlled heat and pressure to the inner eyelid surface, softening and expressing the hardened lipid contents of obstructed meibomian glands. Dr. Hardten's clinical trial demonstrated that a single LipiFlow treatment produced statistically significant improvements in meibomian gland function and dry eye symptoms compared with warm compresses alone, with sustained benefit at four weeks. For patients whose dry eye is primarily driven by MGD, this addresses the root cause rather than managing symptoms downstream.

Intense pulsed light (IPL) therapy: Used for meibomian gland dysfunction related to rosacea and eyelid telangiectasias. Three to four sessions over several months can significantly improve meibomian gland function and tear film stability.

Autologous serum eye drops: Prepared from the patient's own blood serum, these drops contain growth factors and anti-inflammatory proteins not present in artificial tears. Indicated for severe aqueous deficiency, particularly in Sjogren syndrome, and for neuropathic dry eye where the corneal surface requires biological support.

The pain dimension

Dr. Jacobs's contribution to the TFOS DEWS II pain and sensation report is particularly important for patients whose symptoms feel disproportionate to their clinical findings. Neuropathic pain in dry eye — driven by sensitized corneal nerve fibers rather than surface inflammation — does not respond to standard anti-inflammatory drops. These patients may require oral neuromodulators (gabapentin, duloxetine) or topical agents targeting neuropathic pathways. Recognizing this subtype avoids years of ineffective treatment escalation.

Questions to ask your doctor

• Is my dry eye primarily aqueous deficiency, meibomian gland dysfunction, or both, and how does that change my treatment plan?
• Have you evaluated my meibomian glands directly, and are there structural signs of atrophy that warrant a gland-directed treatment like LipiFlow?
• Which prescription anti-inflammatory — cyclosporine or lifitegrast — do you recommend for my specific case, and what is the realistic timeline for improvement?
• Are any of my current medications (antihistamines, blood pressure drugs, antidepressants) worsening my dry eye?
• Should I be using preservative-free formulations for all my eye drops?
• Could my symptoms involve a neuropathic component that standard treatment would not address?

The bottom line

Dry eye disease is a chronic inflammatory condition with a feedback cycle involving the tear film, ocular surface, and meibomian glands — not a simple deficiency of water. When symptoms impair daily activities or the cornea shows damage on exam, prescription anti-inflammatory therapy with cyclosporine or lifitegrast is appropriate and evidence-supported. For patients whose dry eye is primarily driven by meibomian gland dysfunction, procedural treatments like LipiFlow address the structural cause rather than the downstream consequences. Working with a cornea or anterior segment specialist who can characterize the subtype of your dry eye leads to far better outcomes than cycling through lubricating drops indefinitely.